US FDA Approves ZEVASKYN, First And Only Cell-Based Gene Therapy For Patients With Recessive Dystrophic Epidermolysis Bullosa
April 29 (Reuters) - Abeona Therapeutics Inc ABEO.O:
U.S. FDA APPROVES ZEVASKYN™ (PRADEMAGENE ZAMIKERACEL), THE FIRST AND ONLY CELL-BASED GENE THERAPY FOR PATIENTS WITH RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA (RDEB)
ABEONA THERAPEUTICS INC - ZEVASKYN TO BE AVAILABLE THROUGH QUALIFIED TREATMENT CENTERS IN 3Q 2025
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Micron Stock Forecast: Can the AI Memory Super-Cycle Drive MU to $3,000 by 2030?

Tesla Opens Up Over 2%, Shares Return to $400, Here Is What Investors Need to Note

Gold Price Forecast: U.S.-Iran Tensions Ease, Nonfarm Payrolls Looming, What’s Next for Gold?

SpaceX IPO Approaches: Musk Dissolves xAI into SpaceX and Subleases 300MW Compute to Anthropic; Can the $2 Trillion Valuation Hold?

WTI and Brent Futures Both Fall Below $100 Mark, Have Oil Prices and Energy Sector Peaked?

Tradingkey








